|
Gene: PARP10 |
Gene summary for PARP10 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PARP10 | Gene ID | 84875 |
Gene name | poly(ADP-ribose) polymerase family member 10 | |
Gene Alias | ARTD10 | |
Cytomap | 8q24.3 | |
Gene Type | protein-coding | GO ID | GO:0000209 | UniProtAcc | B4E0C4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84875 | PARP10 | LZE4T | Human | Esophagus | ESCC | 2.37e-02 | 8.91e-02 | 0.0811 |
84875 | PARP10 | LZE7T | Human | Esophagus | ESCC | 3.90e-02 | 1.37e-01 | 0.0667 |
84875 | PARP10 | LZE8T | Human | Esophagus | ESCC | 6.71e-04 | 1.35e-01 | 0.067 |
84875 | PARP10 | LZE20T | Human | Esophagus | ESCC | 3.61e-13 | 3.11e-01 | 0.0662 |
84875 | PARP10 | LZE22T | Human | Esophagus | ESCC | 1.40e-06 | 3.42e-01 | 0.068 |
84875 | PARP10 | LZE24T | Human | Esophagus | ESCC | 1.43e-40 | 8.60e-01 | 0.0596 |
84875 | PARP10 | LZE6T | Human | Esophagus | ESCC | 9.61e-05 | 1.83e-01 | 0.0845 |
84875 | PARP10 | P1T-E | Human | Esophagus | ESCC | 5.20e-08 | 3.27e-01 | 0.0875 |
84875 | PARP10 | P2T-E | Human | Esophagus | ESCC | 2.88e-30 | 5.23e-01 | 0.1177 |
84875 | PARP10 | P4T-E | Human | Esophagus | ESCC | 1.78e-10 | 2.01e-01 | 0.1323 |
84875 | PARP10 | P5T-E | Human | Esophagus | ESCC | 1.04e-09 | 1.41e-01 | 0.1327 |
84875 | PARP10 | P8T-E | Human | Esophagus | ESCC | 7.32e-28 | 3.82e-01 | 0.0889 |
84875 | PARP10 | P9T-E | Human | Esophagus | ESCC | 4.80e-25 | 4.69e-01 | 0.1131 |
84875 | PARP10 | P10T-E | Human | Esophagus | ESCC | 1.34e-07 | 7.42e-02 | 0.116 |
84875 | PARP10 | P11T-E | Human | Esophagus | ESCC | 1.44e-21 | 6.74e-01 | 0.1426 |
84875 | PARP10 | P12T-E | Human | Esophagus | ESCC | 1.54e-29 | 5.48e-01 | 0.1122 |
84875 | PARP10 | P15T-E | Human | Esophagus | ESCC | 2.72e-24 | 4.32e-01 | 0.1149 |
84875 | PARP10 | P16T-E | Human | Esophagus | ESCC | 7.52e-20 | 3.01e-01 | 0.1153 |
84875 | PARP10 | P17T-E | Human | Esophagus | ESCC | 2.26e-13 | 4.35e-01 | 0.1278 |
84875 | PARP10 | P19T-E | Human | Esophagus | ESCC | 3.75e-07 | 4.13e-01 | 0.1662 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00507927 | Liver | Cirrhotic | regulation of viral process | 74/4634 | 164/18723 | 9.54e-09 | 3.69e-07 | 74 |
GO:003139612 | Liver | Cirrhotic | regulation of protein ubiquitination | 89/4634 | 210/18723 | 1.40e-08 | 5.30e-07 | 89 |
GO:19039007 | Liver | Cirrhotic | regulation of viral life cycle | 64/4634 | 148/18723 | 6.12e-07 | 1.32e-05 | 64 |
GO:004506912 | Liver | Cirrhotic | regulation of viral genome replication | 41/4634 | 85/18723 | 2.28e-06 | 4.19e-05 | 41 |
GO:000020911 | Liver | Cirrhotic | protein polyubiquitination | 89/4634 | 236/18723 | 6.09e-06 | 9.80e-05 | 89 |
GO:003139712 | Liver | Cirrhotic | negative regulation of protein ubiquitination | 38/4634 | 83/18723 | 2.40e-05 | 3.14e-04 | 38 |
GO:00091654 | Liver | Cirrhotic | nucleotide biosynthetic process | 89/4634 | 254/18723 | 1.45e-04 | 1.40e-03 | 89 |
GO:190332112 | Liver | Cirrhotic | negative regulation of protein modification by small protein conjugation or removal | 40/4634 | 95/18723 | 1.50e-04 | 1.44e-03 | 40 |
GO:19012934 | Liver | Cirrhotic | nucleoside phosphate biosynthetic process | 89/4634 | 256/18723 | 1.97e-04 | 1.82e-03 | 89 |
GO:0048145 | Liver | Cirrhotic | regulation of fibroblast proliferation | 33/4634 | 80/18723 | 8.46e-04 | 6.12e-03 | 33 |
GO:0048144 | Liver | Cirrhotic | fibroblast proliferation | 33/4634 | 81/18723 | 1.09e-03 | 7.59e-03 | 33 |
GO:00190824 | Liver | Cirrhotic | viral protein processing | 15/4634 | 29/18723 | 1.59e-03 | 1.03e-02 | 15 |
GO:00485254 | Liver | Cirrhotic | negative regulation of viral process | 35/4634 | 92/18723 | 3.17e-03 | 1.78e-02 | 35 |
GO:0006301 | Liver | Cirrhotic | postreplication repair | 15/4634 | 31/18723 | 3.68e-03 | 2.02e-02 | 15 |
GO:00450712 | Liver | Cirrhotic | negative regulation of viral genome replication | 22/4634 | 56/18723 | 1.14e-02 | 4.96e-02 | 22 |
GO:00705342 | Liver | Cirrhotic | protein K63-linked ubiquitination | 22/4634 | 56/18723 | 1.14e-02 | 4.96e-02 | 22 |
GO:001603222 | Liver | HCC | viral process | 286/7958 | 415/18723 | 4.41e-28 | 1.86e-25 | 286 |
GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
GO:001905822 | Liver | HCC | viral life cycle | 209/7958 | 317/18723 | 2.05e-17 | 2.09e-15 | 209 |
Page: 1 2 3 4 5 6 7 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PARP10 | SNV | Missense_Mutation | novel | c.1092G>A | p.Met364Ile | p.M364I | protein_coding | tolerated(0.5) | benign(0.003) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PARP10 | SNV | Missense_Mutation | novel | c.2207G>T | p.Arg736Leu | p.R736L | protein_coding | tolerated(0.08) | benign(0.072) | TCGA-AQ-A54N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PARP10 | SNV | Missense_Mutation | novel | c.1847N>C | p.Gly616Ala | p.G616A | protein_coding | tolerated(0.12) | benign(0.042) | TCGA-BH-A0BP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PARP10 | SNV | Missense_Mutation | novel | c.2947N>A | p.Val983Met | p.V983M | protein_coding | tolerated(0.24) | benign(0.285) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PARP10 | SNV | Missense_Mutation | rs782279171 | c.2075N>A | p.Arg692Gln | p.R692Q | protein_coding | tolerated(1) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PARP10 | SNV | Missense_Mutation | rs782036506 | c.626N>A | p.Arg209His | p.R209H | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
PARP10 | SNV | Missense_Mutation | novel | c.2667N>T | p.Glu889Asp | p.E889D | protein_coding | tolerated(0.42) | benign(0) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
PARP10 | SNV | Missense_Mutation | rs782213808 | c.2665N>C | p.Glu889Gln | p.E889Q | protein_coding | tolerated(0.46) | benign(0.011) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
PARP10 | SNV | Missense_Mutation | c.3068N>T | p.Ser1023Phe | p.S1023F | protein_coding | deleterious(0.04) | benign(0.316) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | ||
PARP10 | SNV | Missense_Mutation | novel | c.487N>A | p.Glu163Lys | p.E163K | protein_coding | tolerated(0.5) | benign(0.007) | TCGA-VS-A952-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |